Cidara Therapeutics, Inc.
CDTX
$19.44
$0.261.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -78.62M | -29.52M | -22.65M | -36.27M | -22.93M |
| Total Depreciation and Amortization | 176.00K | 156.00K | 117.00K | 142.00K | 118.00K |
| Total Amortization of Deferred Charges | 16.00K | 40.00K | 53.00K | -382.00K | 77.00K |
| Total Other Non-Cash Items | 4.02M | 3.15M | 3.15M | 4.32M | 4.22M |
| Change in Net Operating Assets | 1.66M | -29.88M | -1.67M | 14.01M | -3.92M |
| Cash from Operations | -72.75M | -56.06M | -21.00M | -18.18M | -22.43M |
| Capital Expenditure | -129.00K | -307.00K | -327.00K | -434.00K | -505.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -129.00K | -307.00K | -327.00K | -434.00K | -505.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -201.00K | -125.00K | -50.00K | -50.00K | -- |
| Issuance of Common Stock | 98.28M | 8.00K | 8.00K | 8.00K | 26.25M |
| Repurchase of Common Stock | -146.00K | -146.00K | -39.00K | -300.00K | -261.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4.00K | -4.00K | -4.00K | -4.00K | -- |
| Cash from Financing | 97.93M | -267.00K | -85.00K | -346.00K | 25.98M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 25.05M | -56.64M | -21.41M | -18.96M | 3.05M |